Erasca Inc (ERAS) - Total Liabilities
Based on the latest financial reports, Erasca Inc (ERAS) has total liabilities worth $67.71 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ERAS net asset momentum to track the company's year-over-year net asset growth rate.
Erasca Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Erasca Inc's total liabilities have evolved over time, based on quarterly financial data.
Erasca Inc Competitors by Total Liabilities
The table below lists competitors of Erasca Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Axfood AB
ST:AXFO
|
Sweden | Skr29.08 Billion |
|
Uipath Inc
NYSE:PATH
|
USA | $1.10 Billion |
|
Inner Mongolia MengDian HuaNeng Thermal Power Corp Ltd
SHG:600863
|
China | CN¥19.26 Billion |
|
Sigma Foods, S.A.B. de C.V.
MX:SIGMAFA
|
Mexico | MX$108.05 Billion |
|
Beijing Jingneng Power Co Ltd
SHG:600578
|
China | CN¥64.24 Billion |
|
Shanghai 2345 Network Holding Group
SHE:002195
|
China | CN¥356.57 Million |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
USA | $3.05 Billion |
|
AB Sagax (publ)
ST:SAGA-B
|
Sweden | Skr47.10 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Erasca Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Erasca Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Erasca Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Erasca Inc (2019–2025)
The table below shows the annual total liabilities of Erasca Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $70.98 Million | -10.18% |
| 2024-12-31 | $79.03 Million | +0.53% |
| 2023-12-31 | $78.61 Million | -23.72% |
| 2022-12-31 | $103.06 Million | +129.59% |
| 2021-12-31 | $44.89 Million | -81.20% |
| 2020-12-31 | $238.81 Million | +245.52% |
| 2019-12-31 | $69.12 Million | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more